We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Combining Multiple Laboratory Techniques Provides Deeper Insights into Deadly Brain Tumors

By LabMedica International staff writers
Posted on 15 May 2025

Glioblastoma (GBM) is a highly aggressive primary brain cancer that currently has limited effective treatments. More...

Stereotactic needle biopsies are commonly employed for diagnosis; however, their use is restricted as physicians typically limit the collection of small tumor samples due to the invasive nature of the procedure, which requires sedation with anesthesia. Tumor samples are usually obtained at the start of treatment and, occasionally, at the end. In a groundbreaking study, a team of researchers has shown that doctors can gather extensive information about a patient’s cancer by applying various laboratory techniques to analyze tumor tissue obtained from needle biopsies of glioblastoma. This work, published in Nature Communications, could also have significant implications for diagnosing and studying other types of cancer.

In the study, clinicians from Johns Hopkins Kimmel Cancer Center (Baltimore, MD, USA) and four other institutions injected a virus designed to target and kill glioblastoma cells directly into the tumor. During the same procedure, surgeons collected tumor tissue samples, which were then analyzed using multiple advanced laboratory techniques, including single-cell RNA sequencing, transcriptomics, metabolomics, proteomics, and immune profiling. These techniques allowed the researchers to demonstrate that even small samples of tumor tissue could provide valuable insights into the tumor's biological characteristics, immune interactions, and molecular pathways. Additionally, the study found that the tissue could be grafted onto a mouse model for further examination and analysis.

“This is a concept that expands beyond just brain cancers,” said study co-author Chetan Bettegowda, M.D., Ph.D. “Whenever people do needle biopsies, it has been just sufficient to study if the tissue is cancerous, what type and maybe some very simple molecular characterization. This brings tissue analysis to the modern age. ... Historically [oncologists] haven’t done repeat biopsies because we felt, ‘Oh, what are we going to get that we don’t already know from the original diagnosis?’ It turns out there’s quite a bit to be learned.”

Related Links:
Johns Hopkins Kimmel Cancer Center


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.